Meet the Investigator

Posted by Steve Bucciarelli - April 1, 2013

VITAL SIGNS NAME: Michael Hayden, CM, OBC, MB, ChB, PhD, FRCP(C), FRSC CURRENT Dr. Michael…

Read More

Meet the Company

Posted by Steve Bucciarelli - April 1, 2013

              VITAL SIGNS NAME: Teva Pharmaceutical Industries, Ltd. HEADQUARTERS:…

Read More

HD Insights Volume 6 (PDF)

Posted by Steve Bucciarelli - February 23, 2013

[pdf-embedder url=”https://huntingtonstudygroup.org/wp-content/uploads/2016/05/vol-6-winter-2013.pdf”]

Read More

HD Insights Volume 3 (PDF)

Posted by Steve Bucciarelli - November 1, 2012

[pdf-embedder url=”https://huntingtonstudygroup.org/wp-content/uploads/2016/05/vol-3-fall-2012.pdf”]

Read More

An Interview with Dr. Nancy Wexler: Discovering the Huntington Disease Gene

Posted by Steve Bucciarelli - September 1, 2012

By: Kristin Darwin One morning in 1968, Dr. Nancy Wexler’s mother, Leonore Wexler, had jury…

Read More

Meet the Company

Posted by Steve Bucciarelli - September 1, 2012

        VITAL SIGNS NAME: Isis Pharmaceuticals HEADQUARTERS: Carlsbad, California STOCK PRICE AS…

Read More

Research Around the World: Chile

Posted by Steve Bucciarelli - September 1, 2012

Alleviating Secretory Pathway Stress in Huntington Disease By: Rene Vidal, PhD and Claudio Hetz, PhD…

Read More

Highlights from the CHDI HD Therapeutics Conference

Posted by Steve Bucciarelli - September 1, 2012

By: Lise Munsie, PhD At the 7th Annual CHDI HD Therapeutics Conference in Palm Springs,…

Read More

The Use of Antisense Oligonucleotides for Gene Silencing

Posted by Steve Bucciarelli - September 1, 2012

By: Emily Mitchell Sontag, PhD Huntington disease (HD) is caused by a single gene mutation…

Read More

Research Round-Up

Posted by Steve Bucciarelli - September 1, 2012

By: Lise Munsie, PhD In the beginning… In the past year, researchers have published on…

Read More